SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients von Jeromin, S, Weissmann, S, Haferlach, C, Dicker, F, Bayer, K, Grossmann, V, Alpermann, T, Roller, A, Kohlmann, A, Haferlach, T, Kern, W, Schnittger, S

Volltext

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes von Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, Schnittger, S, Sanada, M, Kon, A, Alpermann, T, Yoshida, K, Roller, A, Nadarajah, N, Shiraishi, Y, Shiozawa, Y, Chiba, K, Tanaka, H, Koeffler, H P, Klein, H-U, Dugas, M, Aburatani, H, Kohlmann, A, Miyano, S, Haferlach, C, Kern, W, Ogawa, S

Volltext

Landscape of TET2 mutations in acute myeloid leukemia von Weissmann, S, Alpermann, T, Grossmann, V, Kowarsch, A, Nadarajah, N, Eder, C, Dicker, F, Fasan, A, Haferlach, C, Haferlach, T, Kern, W, Schnittger, S, Kohlmann, A

Volltext

The role of different genetic subtypes of CEBPA mutated AML von Fasan, A, Haferlach, C, Alpermann, T, Jeromin, S, Grossmann, V, Eder, C, Weissmann, S, Dicker, F, Kohlmann, A, Schindela, S, Kern, W, Haferlach, T, Schnittger, S

Volltext

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status von Schmidt, M, Rinke, J, Schäfer, V, Schnittger, S, Kohlmann, A, Obstfelder, E, Kunert, C, Ziermann, J, Winkelmann, N, Eigendorff, E, Haferlach, T, Haferlach, C, Hochhaus, A, Ernst, T

Volltext

I-19 Next generation sequencing – Diagnostic/prognostic key? von Kohlmann, A

Volltext

Landmark analysis of DNMT3A mutations in hematological malignancies von Roller, A, Grossmann, V, Bacher, U, Poetzinger, F, Weissmann, S, Nadarajah, N, Boeck, L, Kern, W, Haferlach, C, Schnittger, S, Haferlach, T, Kohlmann, A

Volltext

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome von Schnittger, S, Eder, C, Jeromin, S, Alpermann, T, Fasan, A, Grossmann, V, Kohlmann, A, Illig, T, Klopp, N, Wichmann, H-E, Kreuzer, K-A, Schmid, C, Staib, P, Peceny, R, Schmitz, N, Kern, W, Haferlach, C, Haferlach, T

Volltext

Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients von Weissmann, S, Roller, A, Jeromin, S, Hernández, M, Abáigar, M, Hernández-Rivas, J M, Grossmann, V, Haferlach, C, Kern, W, Haferlach, T, Schnittger, S, Kohlmann, A

Volltext

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis von Fasan, A, Eder, C, Haferlach, C, Grossmann, V, Kohlmann, A, Dicker, F, Kern, W, Haferlach, T, Schnittger, S

Volltext

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases von Grossmann, V, Kohlmann, A, Zenger, M, Schindela, S, Eder, C, Weissmann, S, Schnittger, S, Kern, W, Müller, M C, Hochhaus, A, Haferlach, T, Haferlach, C

Volltext

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease von Kohlmann, A, Nadarajah, N, Alpermann, T, Grossmann, V, Schindela, S, Dicker, F, Roller, A, Kern, W, Haferlach, C, Schnittger, S, Haferlach, T

Volltext

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving... von Kohlmann, A, Klein, H-U, Weissmann, S, Bresolin, S, Chaplin, T, Cuppens, H, Haschke-Becher, E, Garicochea, B, Grossmann, V, Hanczaruk, B, Hebestreit, K, Gabriel, C, Iacobucci, I, Jansen, J H, te Kronnie, G, van de Locht, L, Martinelli, G, McGowan, K, Schweiger, M R, Timmermann, B, Vandenberghe, P, Young, B D, Dugas, M, Haferlach, T

Volltext

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance von Grossmann, V, Kohlmann, A, Eder, C, Haferlach, C, Kern, W, Cross, N C P, Haferlach, T, Schnittger, S

Volltext

High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia von Grossmann, V, Schnittger, S, Poetzinger, F, Kohlmann, A, Stiel, A, Eder, C, Fasan, A, Kern, W, Haferlach, T, Haferlach, C

Volltext

The role of the RAS pathway in iAMP21-ALL von Ryan, S L, Matheson, E, Grossmann, V, Sinclair, P, Bashton, M, Schwab, C, Towers, W, Partington, M, Elliott, A, Minto, L, Richardson, S, Rahman, T, Keavney, B, Skinner, R, Bown, N, Haferlach, T, Vandenberghe, P, Haferlach, C, Santibanez-Koref, M, Moorman, A V, Kohlmann, A, Irving, J A E, Harrison, C J

Volltext

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced o... von Soria, J.-C., Fülöp, A., Maciel, C., Fischer, J.R., Girotto, G., Lago, S., Smit, E., Ostoros, G., Eberhardt, W.E.E., Lishkovska, P., Lovick, S., Mariani, G., McKeown, A., Kilgour, E., Smith, P., Bowen, K., Kohlmann, A., Carlile, D.J., Jänne, P.A.

Volltext

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics von Grossmann, V, Bacher, U, Haferlach, C, Schnittger, S, Pötzinger, F, Weissmann, S, Roller, A, Eder, C, Fasan, A, Zenger, M, Staller, M, Kern, W, Kohlmann, A, Haferlach, T

Volltext

Gene expression profiling in MDS and AML: potential and future avenues von Theilgaard-Mönch, K, Boultwood, J, Ferrari, S, Giannopoulos, K, Hernandez-Rivas, J M, Kohlmann, A, Morgan, M, Porse, B, Tagliafico, E, Zwaan, C M, Wainscoat, J, Van den Heuvel-Eibrink, M M, Mills, K, Bullinger, L

Volltext

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, mole... von Flach, J, Dicker, F, Schnittger, S, Schindela, S, Kohlmann, A, Haferlach, T, Kern, W, Haferlach, C

Volltext